Muscarinic Receptor Agonists and Antagonists
Open Access
- 28 February 2001
- Vol. 6 (3) , 142-193
- https://doi.org/10.3390/60300142
Abstract
A comprehensive review of pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists is presented. The therapeutic benefits of achieving receptor subtype selectivity are outlined and applications in the treatment of Alzheimer’s disease are discussed. A selection of chemical routes are described, which illustrate contemporary methodology for the synthesis of chiral medicinal compounds (asymmetric synthesis, chiral pool, enzymes). Routes to bicyclic intrannular amines and intramolecular Diels-Alder reactions are highlighted.Keywords
This publication has 183 references indexed in Scilit:
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Discovery & development of selective M3 antagonists for clinical useLife Sciences, 1997
- Muscarinic agonists in Alzheimer's diseaseLife Sciences, 1997
- Muscarinic m1 receptor agonists increase the secretion of the amyloid precursor protein ectodomainLife Sciences, 1997
- Muscarinic receptor subtype selective toxinsLife Sciences, 1997
- Tolterodine-a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical dataLife Sciences, 1997
- Muscarinic receptor subtypes in airwaysLife Sciences, 1993
- Therapeutic potential of CNS-active M2 antagonists: Novel structures and pharmacologyLife Sciences, 1993
- The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivoLife Sciences, 1993
- m1-toxinLife Sciences, 1993